Skip to main content

Table 1 Basic demographic data of patients with BCLC stage B hepatocellular carcinoma of various treatments

From: Comparison of overall survival on surgical resection versus transarterial chemoembolization with or without radiofrequency ablation in intermediate stage hepatocellular carcinoma: a propensity score matching analysis

VariableSR (n = 140)TACE (n = 231)TACE+RFA (n = 57)Total (n = 428)P-value
Male117 (83.6)173 (74.9)43 (75.4)333 (77.8)0.134
Age (years)62 (35–82)64 (29–91)64 (28–86)63 (25–91)0.311
Smoking68 (48.6)113 (48.9)27 (47.4)208 (48.6)0.978
Alcohol use58 (41.4)100 (43.3)23 (40.4)181 (42.3)0.894
HBV positive70 (50.0)103 (44.6)32 (56.1)205 (47.9)0.245
HCV positive30 (21.4)90 (39.0)21 (36.8)141 (32.9)0.002
Total Bilirubin1.03 ± 0.431.34 ± 1.141.40 ± 0.661.24 ± 0.910.003
INR1.00 ± 0.061.06 ± 0.121.10 ± 0.141.05 ± 0.11< 0.0001
Cirrhosis36 (25.7)155 (67.1)43 (75.4)234 (54.7)< 0.0001
Child-Pugh class A134 (95.7)194 (84.0)44 (77.2)372 (86.9)< 0.0001
Tumor size8.2 ± 3.37.0 ± 3.85.5 ± 2.67.0 ± 3.60.001
Tumor size≥5 cm127 (90.7)149 (64.5)25 (43.8)289 (67.5)< 0.0001
Tumor number (≥3)49 (35.0)178 (77.1)51 (89.5)278 (65.0)< 0.0001
AFP (ng/mL) ≥ 20034 (24.3)50 (21.6)7 (12.1)91(21.3)0.171
Mortality50 (35.7)173 (74..9)34 (59.6)257 (60.0)< 0.0001
Follow-up times (months)39 (1–98)22 (1–97)37 (3–95)29 (1–98)< 0.001
  1. BCLC stage Barcelona clinic liver cancer; SR Surgical resection; TACE Transcatheter arterial chemoembolization; RFA Radiofrequency ablation; HBV Hepatitis B virus; HCV Hepatitis C virus; AFP: INR International normalize ratio; Alpha-fetoprotein;